Amazing! 20 varieties of Shiyao group have been evaluated and 8 heavyweight varieties have been approved

In the past 2019, 14 varieties of Shiyao group have passed the consistency evaluation, and 20 varieties have passed the evaluation; 8 heavy-duty generic drugs have been approved and listed, and clopidogrel has won the bid for centralized collection; a number of new anti-tumor drugs have obtained clinical licenses, and L-amlodipine maleate tablets have entered the U.S market; innovative anti-tumor drugs have shouldered the banner of performance growth In 2020, the key play of the pharmaceutical industry - the opening of the second batch of volume purchase is imminent, and the performance of the five varieties of Shiyao group included in the centralized procurement once again attracts people's attention Recently, sunitinib malate capsules and pramipexole hydrochloride tablets of Shiyao group were approved for marketing simultaneously, and were deemed to have passed the consistency evaluation Sunitinib malate capsule is the first one in China, pramipexole hydrochloride tablet is the second one approved in China It is worth noting that pramipexole hydrochloride is the first evaluated anti Parkinson's disease drug in China, further enriching the product line of Shiyao group In 2019, it was the peak of consistency evaluation varieties of Sinopharm group In 2018, six varieties of Sinopharm group, including amoxicillin capsule, azithromycin tablet, captopril tablet, tramadol hydrochloride tablet, metformin hydrochloride tablet and paclitaxel for injection (albumin binding type), passed the consistency evaluation In 2019, Sinopharm group added another 14 varieties According to the data of minenet, up to now, there are 20 varieties of Shiyao group that have passed the consistency evaluation Among them, 6 varieties of Ibuprofen Tablets, ranitidine hydrochloride capsules, cefadroxil tablets, pramipexole hydrochloride tablets, tramadol hydrochloride tablets and sunitinib malate capsules are the exclusive ones Among the 20 evaluated varieties, 7 are systemic antibacterials, involving azithromycin, clindamycin, cephalosporins and amoxicillin, which shows the importance of consistency evaluation of antibiotics in Shiyao group According to the data of minenet, in 2018, the total sales volume of anti bacteria drugs for general use in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) was 158.9 billion yuan The consistency evaluation of antibiotic drug layout is conducive to the consolidation of the company's products market Shiyao group passed the consistency evaluation With the approval of sunitinib malate capsules and pramipexole hydrochloride tablets, 8 varieties of Shiyao group have been approved for production since 2019 The varieties previously approved were dronedarone, glutathione, metformin, tegrilol, clopidogrel and ambroxol It is worth noting that although the registration type of clopidogrel bisulfate tablets of Shiyao group is imitation 6, they are reviewed according to the new classification, approved for production and deemed to pass the consistency evaluation In the "4 + 7" expansion, there are three winning enterprises of clopidogrel bisulfate tablets (75mg) including Petrochemicals Group, Sanofi and Lepu pharmaceutical, and the lowest price is 2.44 yuan / tablet selected by Encun of Petrochemicals Group In front of the volume procurement with consistency evaluation as the threshold, Sinopharm group has the honor to overtake and win the bid for centralized procurement in the new classification evaluation, while in the situation of "three over evaluation + original research", xinlitai is out due to the high price 8 varieties approved by Sinopharm group in 2019 The second batch of purchased varieties will be opened on January 17th 5 varieties of Shiyao group were selected, including Azithromycin Tablets, Cefalexin Capsules, Amoxicillin Capsules, Clindamycin Hydrochloride Capsules and Paclitaxel For Injection (albumin binding type) According to the consistency evaluation database of minenet, among the five second batch of collected varieties that have been evaluated by Shiyao group, there are two and three enterprises that have been evaluated for azithromycin tablets and paclitaxel for injection (albumin binding type), five, six and nine enterprises that have been evaluated for Cefalexin Capsules, clindamycin hydrochloride capsules and Amoxicillin Capsules, respectively, with especially fierce competition On the day of the bid opening on January 17, how will the group deal? We'll see! Competition pattern of the second batch of centralized procurement varieties of Shiyao group As a leading comprehensive pharmaceutical enterprise in China, Shiyao Group actively transformed and innovated drug research and development and opened up overseas market at the time of brand shuffling and integration of pharmaceutical industry In the United States and Australia, new drug clinical trials have been advancing, and Levoamlodipine Maleate Tablets has become the first China's indigenous innovative drug approved by FDA In 2019, Sinopharm group made rapid reports in new drug research and development, and many new anti-tumor drugs obtained clinical licenses, including anti-tumor nano drugs (epirubicin hydrochloride liposome injection), new target anti-tumor drugs (syha1807 and syha1801), breast cancer drugs (paclitaxel cationic liposome for injection), intrahepatic cholangiocarcinoma and urothelial cell carcinoma drugs (syha1803) and malignant tumor Tumor ascites drugs (recombinant anti EpCAM and CD3 human mouse chimeric bispecific antibody for injection), bone cancer drugs (almb-0168), etc Notice on new drug research and development issued by Sinopharm group in 2019 In recent years, the performance of Sinopharm group has continued to grow at a high speed, with both revenue and net profit showing a considerable upward trend The sales of the anti-tumor drug portfolio also maintained a strong growth, with 208% growth in 2019q1, 194.2% growth in 2019h1 and 170.7% growth in 2019q3 The strong sales growth promoted the company to increase investment in drug research and development At present, the group has about 300 innovative drug product projects, including 30 new target macromolecular biological drugs, 40 new small molecule drugs and more than 70 new protochemical drugs.